KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Operating Expenses: 2019-2025

Historic Operating Expenses for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $182.1 million.

  • Royalty Pharma's Operating Expenses rose 206.90% to $182.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $817.2 million, marking a year-over-year increase of 13.16%. This contributed to the annual value of $971.1 million for FY2024, which is 12.61% up from last year.
  • As of Q3 2025, Royalty Pharma's Operating Expenses stood at $182.1 million, which was down 50.62% from $368.9 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Operating Expenses high stood at $1.0 billion for Q4 2022, and its period low was -$190.0 million during Q2 2021.
  • Its 3-year average for Operating Expenses is $219.9 million, with a median of $232.1 million in 2024.
  • As far as peak fluctuations go, Royalty Pharma's Operating Expenses plummeted by 287.02% in 2021, and later spiked by 1,479.41% in 2024.
  • Royalty Pharma's Operating Expenses (Quarterly) stood at $422.3 million in 2021, then spiked by 148.27% to $1.0 billion in 2022, then slumped by 101.61% to -$16.8 million in 2023, then spiked by 1,479.41% to $232.1 million in 2024, then surged by 206.90% to $182.1 million in 2025.
  • Its Operating Expenses was $182.1 million in Q3 2025, compared to $368.9 million in Q2 2025 and $34.1 million in Q1 2025.